Key result
Fas/FADD activation drives vascular smooth muscle MCP-1 expression via calpain- and caspase-8-dependent IL-1alpha signaling.
Answers are grounded in this paper and cite their sources.
We previously reported that treatment of human vascular smooth muscle cells (SMCs) with proapoptotic stimuli, including Fas ligand plus cycloheximide (FasL/Chx), or overexpression of Fas-associated death domain protein (FADD) result in increased expression of monocyte chemoattractant protein-1 (MCP-1) and other proinflammatory genes. In this study, we demonstrate that Fas/FADD-induced MCP-1 upregulation is driven by an autocrine/paracrine signaling loop in which interleukin (IL)-1alpha synthesis and release are activated through caspase- and calpain-dependent processes. Untreated SMCs contain very little IL-1alpha protein or transcript. Both were increased greatly in response to Fas/FADD activation, primarily through an autocrine/paracrine pathway in which secreted IL-1alpha stimulated additional IL-1alpha synthesis and release. Caspase 8 (Csp8) activity increased in response to FasL/Chx treatment, and Csp8 inhibitors markedly reduced IL-1alpha release and MCP-1 upregulation. In contrast, Csp8 activity was not significantly increased in response to FADD overexpression and caspase inhibitors did not effect FADD-induced MCP-1 upregulation. Both FasL/Chx treatment and FADD overexpression increased the activity of calpains. Calpain inhibitors reduced IL-1alpha release and MCP-1 upregulation in both FADD-overexpressing SMCs and FasL/Chx-treated SMCs without blocking Csp8 activity. This indicates that calpains are not required for activation of caspases and that caspase activation is not sufficient for IL-1alpha release and MCP-1 upregulation. These data suggest that calpains play a dominant role in Fas/FADD-induced IL-1alpha release and MCP-1 upregulation and that caspase activation may function to amplify the effects of calpain activation.
No takes yet. Share an insight, caveat, or question.
Schaub et al. (2003) studied Vascular inflammation / smooth muscle cell apoptosis signaling. Fas ligand plus cycloheximide (FasL/Chx) treatment or FADD overexpression, with caspase or calpain inhibitors vs. Untreated human vascular smooth muscle cells was evaluated on Interleukin-1alpha (IL-1alpha) synthesis/release and monocyte chemoattractant protein-1 (MCP-1) expression. Fas/FADD activation in human smooth muscle cells upregulates MCP-1 expression through a calpain- and caspase-8-dependent autocrine/paracrine IL-1alpha signaling loop.
Synapse has enriched 10 related papers. Consider them for comparative context: